Here is the design of a clinical trial:

Official Title: Mesothelioma and Radical Surgery 2: a Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no (Extended) Pleurectomy Decortication for Patients With Malignant Pleural Mesothelioma (Mars 2).

Included conditions:
- Mesothelioma

Study Armgroups:
- {'label': 'Surgery', 'type': 'EXPERIMENTAL', 'description': '(Extended) pleurectomy decortication', 'interventionNames': ['Procedure: (Extended) pleurectomy decortication']}
- {'label': 'no surgery', 'type': 'NO_INTERVENTION', 'description': 'no surgery'}

Interventions:
- {'type': 'PROCEDURE', 'name': '(Extended) pleurectomy decortication', 'armGroupLabels': ['Surgery']}

Primary Outcomes:
- {'measure': 'Survival', 'description': 'The time from randomisation to death will be measured and date of death will be collected on purposely designed case report forms.', 'timeFrame': '24 months'}

Please estimate the sample size based on the assumption: 
The study is designed to have 80% power to detect the specified HR at a 5% significance level (two-sided). It also accounts for a 10% cross-over rate from the medical to surgery groups.
Sample size
        The total sample size has been set at 328 participants (164 per group). The patients randomised in the pilot trial will contribute to the total sample size. The study will have 80% power to detect a HR of 0.7 at 5% statistical significance (two-sided), modelled on a published assumption of a median survival time of 16.8 months in patients with mesothelioma who were fit enough to receive surgery, but did not have it17 and allowing for 10% cross-over from the medical to surgery groups (as noted in previous trials such as MARS).7 Cross-over will be minimised through instruction (ie, recruit only patients who have equipoise from the outset) and education.
        The relative difference of 30% (HR 0.7) was regarded as the minimally important difference for patients and clinicians to choose surgery given the risks of the procedure. The figure was chosen by the trialâs patient and public involvement (PPI) group. The possibility that survival could be worse with surgery was also discussed, and a relative difference of 30% was also regarded as an appropriate difference to indicate harm, therefore a two-tailed test for superiority was agreed.